⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17918159 | 0.77 | — | — | |
| SCHEMBL5278090 | 0.72 | — | — | |
| SCHEMBL416907 | 0.65 | — | — | |
| SCHEMBL12465346 | 0.63 | DYRK1A (0.48) | — | |
| SCHEMBL19655025 | 0.62 | DYRK1A (0.35) | — | |
| SCHEMBL9865874 | 0.61 | — | — | |
| SCHEMBL8313361 | 0.61 | — | — | |
| SCHEMBL5334854 | 0.61 | — | — | |
| SCHEMBL7407955 | 0.61 | — | — | |
| SCHEMBL9026428 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2023187715-A1 | COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-10-05 | — | — | WO | disclosed |
| US-20230242546-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | SUDO BIOSCIENCES LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| WO-2023139534-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| US-20230183264-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| WO-2021150700-A1 | N-SUBSTITUTED-3-TRICYCLYL PIPERIDINE DERIVATIVES AS ANTICANCER AND NEUROPROTECTIVE AGENTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-07-29 | — | — | WO | disclosed |
| US-10730837-B2 | Modified amino acids | SUTRO BIOPHARMA, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-10633371-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20200039968-A9 | EZH2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20080182838-A1 | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK CANADA INC. (CA) | 2008-07-31 | — | — | US | disclosed |
| US-7393851-B2 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7304048-B2 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1859781-A2 | Brightening and/or colouring agent with triazoles | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-11-28 | — | — | EP | disclosed |
| US-7291613-B2 | Inhibitors of p38 kinase | SCIOS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20070185112-A1 | PIPERIDINE/PIPERAZINE-TYPE INHIBITORS OF P38 KINASE | SCIOS, INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070161649-A1 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE | SCIOS INC. | 2007-07-12 | — | — | US | disclosed |
| US-7238712-B2 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7214679-B2 | Piperidine/piperazine-type inhibitors of p38 kinase | SCIOS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7169800-B2 | Imidazole compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-01-30 | — | — | US | disclosed |